期刊文献+

吉西他滨联合替吉奥治疗晚期胆囊癌的疗效 预览

Curative Effect of Gemcitabine Combined with S-1 on Advanced Gallbladder Cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨吉西他滨联合替吉奥治疗晚期胆囊癌的临床疗效。方法将80例晚期胆囊癌患者按治疗方法的不同分为对照组(n=38)和观察组(n=42例)。2组均在化疗前常规预防性应用5-羟色胺3(5-HT3)受体拮抗剂止吐治疗,同时给予替吉奥胶囊治疗。在此基础上,观察组给予注射用盐酸吉西他滨治疗。观察2组治疗前、治疗2个周期后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、神经元特异性烯醇化酶(NSE)]水平及临床疗效。结果观察组总有效率为64.29%,高于对照组的28.95%(P<0.05)。2组治疗前血清CEA、CA125、CA19-9、NSE水平比较差异无统计学意义(P>0.05),观察组治疗2个周期后血清CEA、CA125、CA19-9、NSE水平均低于对照组(均P<0.05)。结论与替吉奥单药治疗相比,吉西他滨联合替吉奥治疗晚期胆囊癌的疗效更好。 Objective To explore the curative effect of gemcitabine combined with S-1 on advanced gallbladder cancer.Methods Eighty patients with advanced gallbladder cancer were divided into control group(n=38)and observation group(n=42).Both groups were treated with prophylactic serotonin 3(5-HT3)receptor antagonist and S-1 capsules.Additionally,the observation group was given gemcitabine hydrochloride.Serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)and neuron-specific enolase(NSE)levels and clinical curative effect were observed after 2 cycles of treatment.Results The total effective rate in observation group(64.29%)was higher than that in control group(28.95%)(P<0.05).There were no significant differences in serum CEA,CA125,CA19-9 and NSE levels between the two groups before treatment(P>0.05).After treatment,the levels of CEA,CA125,CA19-9 and NSE in observation group were lower than those in control group(P<0.05).Conclusion The combination of gemcitabine and S-1 is superior to S-1 alone for treating advanced gallbladder cancer.
作者 常占国 CHANG Zhan-guo(Department of Medical Oncology,Nanyang First People’s Hospital,Nanyang 473000,China)
出处 《实用临床医学(江西)》 CAS 2018年第12期22-23,26共3页 Practical Clinical Medicine
关键词 胆囊癌 晚期 吉西他滨 替吉奥 肿瘤标志物 疗效 gallbladder cancer,advanced gemcitabine S-1 tumor markers curative effect
作者简介 常占国(1973—),男,本科,副主任医师,主要从事肿瘤疾病的诊治研究。
  • 相关文献

参考文献8

二级参考文献148

  • 1高峻,韩殿冰,张朝.胆囊癌临床研究进展[J].河南外科学杂志,2010(2):88-89. 被引量:15
  • 2山顺林,单鹄声,张闯.以奈达铂与顺铂为主的联合化疗对晚期恶性肿瘤的疗效比较[J].肿瘤研究与临床,2008(10):688-689. 被引量:3
  • 3Alwaili K, Alrasadi K, Awan Z, et al. Approach to the diagnosis and management of lipoprotein disorders [J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16(2): 132-140. 被引量:1
  • 4Therond P. Catabolism of lipoproteins and metabolic syndrome [J]. Curt Opin Endocrinol Diabetes obes, 2009,12(4):366-371. 被引量:1
  • 5Willemsen AE, van Herpen CM, Wesseling P, et al. Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line pall- iative treatment for metastasized ductal breast carcinoma [J]. Acta oncol, 2011, 50(3):462-465. 被引量:1
  • 6Duraker N, Demir D, Bati B, et al. Survival benefit of post-mastecto- my radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis[J]. Jpn J Clin Oneol, 2012, 42 (7):601-608. 被引量:1
  • 7Xu Q, Xu N, Fang W, et al. Complete remission of platinum-refracto- ry primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature [J]. Oneol Lett, 2013, 5(5): 1601-1604. 被引量:1
  • 8Leonardi V, Palmisano V, Pepe A, et al. Docetaxel and gemcitabine in the treatment of metastatic breast carcinoma: a dose finding study [J]. Tumori, 2009, 95(4):427-431. 被引量:1
  • 9Estephan F, Valero V, Esteva FJ, et al. Phase I study of prolonged-in- fusion gemcitabine combined with cyclophosphamide in patients withmetastatic carcinoma of the breast: tolerability of an optimal dose schedule [J]. Oncology, 2009, 77(1):63-70. 被引量:1
  • 10Funakoshi S, Hashiguchi A, Teramoto K, et al. Second-line chemoth- erapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature [J]. Oncol Lett, 2013,5(1):117-122. 被引量:1

共引文献75

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈